Adebrelimab versus serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis in China.

IF 2.6 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

International Journal of Technology Assessment in Health Care Pub Date : 2024-12-02 DOI:10.1017/S0266462324000175

Wanglong Hong, Aizong Shen, Miaomiao Zheng, Wentao Zhu, Guoqiang Ma

引用次数: 0

查看原文本刊更多论文

阿德来单抗与serplulimab +化疗作为一线治疗广泛期小细胞肺癌：中国的成本-效果分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Technology Assessment in Health Care 医学-公共卫生、环境卫生与职业卫生

CiteScore

4.40

自引率

15.60%

发文量

116

审稿时长

6-12 weeks

期刊介绍： International Journal of Technology Assessment in Health Care serves as a forum for the wide range of health policy makers and professionals interested in the economic, social, ethical, medical and public health implications of health technology. It covers the development, evaluation, diffusion and use of health technology, as well as its impact on the organization and management of health care systems and public health. In addition to general essays and research reports, regular columns on technology assessment reports and thematic sections are published.